The efficacy assessment of a self-administered immunotherapy protocol

摘要: Background We previously reported the safety of a self-administered subcutaneous immunotherapy (SCIT) protocol. Here we report results retrospective efficacy trial United Allergy Service (UAS) SCIT We hypothesized that by utilizing slow buildup phase, designed to attain recommended allergen concentrations on cumulative basis, efficacious outcomes and clinical relevance would be achieved. Methods We enrolled 60 patients 56 control patients. The study contrasted baseline treatment period combined symptom plus medication scores (CSMS) as primary outcome measure rhinoconjunctivitis quality life questionnaire (RQLQ) secondary measure. Changes in pollen counts were also examined with regard effects these parameters. Results The group showed significantly improved CSMS (standardized mean difference [SMD]: −1.57; 95% confidence interval [CI], −1.97 −1.18; p < 0.001) RQLQ (SMD: −0.91; CI, −1.23 −0.59; 0.001). These measures respectively 33% 29% compared greater than 40% comparison (p 0.0001). Significant shown when examining regards either monotherapy or poly-allergen SCIT. Furthermore, recent meta-analyses studies equivalent relevance. Assessment during periods further corroborated UAS protocol. Conclusion These results, our previous show carefully implemented protocol is safe.